Effect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients (SBA-APRV)
A Randomized Controlled Trial Of The Effect Of Spontaneous Breathing In APRV Mode On Respiratory Physiology In Patients With Acute Respiratory Distress Syndrome
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Acute respiratory distress syndrome (ARDS) is a life-threatening critical respiratory illness characterized by heterogeneous pulmonary injury and severe ventilation-perfusion mismatch. Airway Pressure Release Ventilation (APRV) permits spontaneous breathing throughout the whole respiratory cycle, which may improve regional ventilation-perfusion matching and hemodynamic status. Nevertheless, excessive spontaneous breathing effort may trigger pendelluft phenomenon, augment regional lung strain and precipitate patient-self-inflicted lung injury (P-SILI). To date, the safe intensity range of spontaneous breathing during APRV for moderate-to-severe ARDS patients has not been well defined.
This single-center, randomized 3-period crossover self-controlled physiological trial enrolls ICU adult patients aged 18-80 years, diagnosed with moderate-to-severe ARDS (PaO₂/FiO₂ ≤ 150 mmHg) within 48-hours of invasive mechanical ventilation. After written informed consent obtained from legal surrogates, subjects will first receive a 60-minute baseline ventilation period following ARDSnet low-tidal-volume pressure-control ventilation strategy under deep sedation without spontaneous breathing. Subsequently, every participant will undergo three APRV intervention states in computer-generated random order: Condition A: APRV with low-intensity spontaneous breathing (spontaneous-contributed minute ventilation 10%-30%); Condition B: APRV with high-intensity spontaneous breathing (31%-50%); Condition C: APRV with fully suppressed spontaneous breathing via deep sedation (RASS -4 to -5). Each intervention maintains target spontaneous-breathing intensity for 30-minute stabilization before data collection. A mandatory 30-minute wash-out phase will be implemented between successive interventions to revert subjects back to baseline pressure-control ventilation and sedation status.
Primary endpoint is the comparison of ventilation-perfusion mismatch percentage (mismatch%, calculated as sum of dead-space fraction and shunt fraction) among three states measured by bedside EIT. Secondary endpoints contain multiple EIT quantitative indices, respiratory mechanics parameters (including esophageal-pressure-derived transpulmonary pressure), hemodynamic and right-ventricular function, diaphragmatic ultrasound indices, arterial blood gas variables. Adverse events related to respiratory, circulatory and operational procedures are closely monitored as safety outcomes.
Planned sample size is 14-16 enrolled participants to achieve 12 evaluable subjects completing all three intervention sequences considering dropout rate. All ventilator and sedation modifications are short-term and reversible; standard clinical therapeutic regimens will not be altered except for study-related procedures. After finishing all three intervention periods, ventilator and sedation settings will be returned to clinical team's discretion. Linear mixed-effect models will be applied for statistical analysis of crossover-design data.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Xiaojing Zou
- Número de telefone: +86-27-85351606
- E-mail: 249126734@qq.com
Locais de estudo
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Contato:
- Xiaojing Zou
- Número de telefone: +86-27-85351606
- E-mail: 249126734@qq.com
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
1. Age ≥18 and ≤80 years old. 2. Diagnosed with moderate-to-severe ARDS according to the 2023 global ARDS definition.
3. Within 48 hours of invasive mechanical ventilation. After 1-hour low-tidal-volume pressure-controlled ventilation following ARDSnet strategy, arterial blood gas shows PaO₂/FiO₂ ≤ 150 mmHg.
4. Written informed consent is obtained from the patient or their legal surrogate decision-maker after full explanation of the study by the principal investigator or authorized study physician.
Exclusion Criteria:
1. Refractory shock defined as persistent hyperlactatemia and/or prolonged capillary refill time, fluid-resistant, requiring norepinephrine ≥ 0.5 μg/kg/min.
2. Severe chronic medical conditions severely affecting cardiopulmonary function: severe chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, right-heart failure, pulmonary hypertension, or severe arrhythmia.
3. Radiologically confirmed bronchopleural fistula, status post lobectomy, or other major thoracic surgery.
4. Contraindications to electrical impedance tomography (EIT): extensive chest skin injury or infection, implanted cardiac pacemaker or defibrillator, etc.
5. Contraindications for esophageal manometry placement: esophageal obstruction, perforation, severe esophageal varices, etc.
6. Diaphragmatic hernia, severe chest wall deformity, or significant pulmonary bullae.
7. Significant coagulation abnormalities (PT or APTT prolonged ≥2 times upper limit of normal, or INR>2.0) with active bleeding risk.
8. Severe intracranial hypertension (>20 mmHg), severe traumatic brain injury (GCS ≤8), or neuromuscular disorders.
9. Pregnant or breastfeeding women. 10. Patients already receiving ECMO therapy. 11. Expected survival time <24 hours judged by attending physician. 12. Body mass index (BMI) >35 kg/m². 13. Previously enrolled in this study or participating in other interventional clinical trials.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Low-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 10%-30%.
A stabilization period of 30 minutes is performed before data collection
|
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 10%-30%.
30-minute stabilization before outcome measurement.
|
|
Experimental: High-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 31%-50%.
A stabilization period of 30 minutes is performed before data collection.
|
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 31%-50%.
30-minute stabilization before outcome measurement.
|
|
Experimental: Fully suppressed spontaneous breathing under APRV
APRV ventilation with spontaneous breathing completely suppressed by deep sedation (RASS-4 to -5).
A stabilization period of 30 minutes is performed before data collection.
|
APRV ventilation mode, spontaneous breathing fully suppressed by deep sedation (RASS-4 to -5).
30-minute stabilization before outcome measurement.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Ventilation-perfusion mismatch percentage (Mismatch%)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Ventilation-perfusion mismatch percentage (Mismatch%), calculated as the sum of dead-space percentage and shunt percentage measured by electrical impedance tomography (EIT).
A composite index reflecting overall ventilation-perfusion mismatch, assessed at baseline and under three APRV experimental conditions.
Unit: %
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Match percentage(match%)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Match percentage derived from electrical impedance tomography (EIT).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Pendelluft amplitude
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pendelluft amplitude derived from electrical impedance tomography (EIT).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Dead-space percentage
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Dead-space percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Shunt percentage
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Intrapulmonary shunt percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Global inhomogeneity index (GI)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period
|
Global inhomogeneity index (GI) derived from electrical impedance tomography (EIT).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period
|
|
Center of ventilation (CoV)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Center of ventilation (CoV) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Tidal recruitment-derecruitment
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Tidal recruitment-derecruitment (Tidal R/D) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Ventilation distribution
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Regional ventilation distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Perfusion distribution
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Regional pulmonary perfusion distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Peak airway pressure (Ppeak)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Airway peak pressure (Ppeak) measured by mechanical ventilator, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Plateau pressure (Pplat)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Airway plateau pressure (Pplat) obtained from end-inspiratory hold maneuver, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Driving pressure (ΔP)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Driving pressure (ΔP) derived from mechanical ventilator measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Static respiratory system compliance (Cstat)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Static respiratory system compliance (Cstat), assessed at baseline and under three APRV experimental conditions.
Unit: mL/cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-inspiratory esophageal pressure (PesI)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-inspiratory esophageal pressure (PesI) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-expiratory esophageal pressure (PesE)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-expiratory esophageal pressure (PesE) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Esophageal pressure swing (ΔPes)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Esophageal pressure swing (ΔPes) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-inspiratory transpulmonary pressure (PtpI)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-inspiratory transpulmonary pressure (PtpI) derived from airway and esophageal pressure measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Transpulmonary driving pressure (ΔPtp)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Transpulmonary driving pressure (ΔPtp) derived from airway and esophageal pressure measurements.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
End-expiratory transpulmonary pressure (PtpE)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
End-expiratory transpulmonary pressure (PtpE) derived from airway and esophageal pressure, assessed at baseline and under three APRV experimental conditions.
Unit: cmH₂O.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Esophageal pressure-time product per minute (PTPes/min)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Esophageal pressure-time product per minute (PTPes/min) read directly from the ventilator interface.
Unit: cmH₂O·s/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Dynamic transpulmonary driving pressure (ΔPL,dyn)
Prazo: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Dynamic transpulmonary driving pressure (ΔPL,dyn) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O.
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Inspiratory muscle pressure (Pmus)
Prazo: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Inspiratory muscle pressure (Pmus) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
End-expiratory occlusion pressure (ΔPocc)
Prazo: At the end of each 30-minute APRV experimental condition (after stabilization)
|
End-expiratory occlusion pressure (ΔPocc) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Airway occlusion pressure (P0.1)
Prazo: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Airway occlusion pressure (P0.1) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Muscular pressure index (PMI)
Prazo: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Muscular pressure index (PMI) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Negative inspiratory force (NIF)
Prazo: At the end of each 30-minute APRV experimental condition (after stabilization)
|
Negative inspiratory force (NIF) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort.
Unit: cmH₂O
|
At the end of each 30-minute APRV experimental condition (after stabilization)
|
|
Heart rate
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Heart rate from continuous bedside monitoring, assessed at baseline and under three APRV experimental conditions.
Unit: beats per minute.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Mean arterial pressure (MAP)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Mean arterial pressure (MAP) measured via invasive arterial catheter, assessed at baseline and under three APRV experimental conditions.
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Vasopressor dosage (μg/kg/min)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Dosage of vasoactive medications, assessed at baseline and under three APRV experimental conditions.
Unit: μg/kg/min
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Central venous pressure (CVP)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Central venous pressure (CVP), assessed at baseline and under three APRV experimental conditions.
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Right-ventricular fractional area change
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Right-ventricular fractional area change measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Velocity-time-integral (VTI)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: cm.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Tricuspid annular plane systolic excursion (TAPSE)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Tricuspid annular plane systolic excursion (TAPSE) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: mm.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Cardiac output (CO)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Cardiac output (CO) calculated from velocity-time integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: L/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Stroke volume (SV)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Stroke volume (SV) calculated from velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions.
Unit: mL.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Diaphragm displacement
Prazo: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Diaphragm displacement measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present.
Unit: mm.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Diaphragm thickening fraction
Prazo: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Diaphragm thickening fraction measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present.
Unit: %.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Lung 12-zone ultrasound score
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Lung ultrasound score based on 12-zone lung ultrasound assessment, assessed at baseline and under three APRV experimental conditions.
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Overdistension (OD) pixel count
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung overdistension (OD), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Overdistension (OD) proportion
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung overdistension (OD) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Recruitment (CR) pixel count
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung recruitment (CR), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Recruitment (CR) proportion
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung recruitment (CR) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Atelectasis (AT) pixel count
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Pixel count of lung atelectasis (AT), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: pixels.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Atelectasis (AT) proportion
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Proportion of lung atelectasis (AT) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence and severity of adverse events
Prazo: During each APRV experimental intervention period
|
Incidence and severity of adverse events during study interventions, focusing on respiratory events, circulatory events and procedure-related adverse events.
Unit: unitless.
|
During each APRV experimental intervention period
|
|
Rate of premature intervention discontinuation for safety concerns
Prazo: During each APRV experimental intervention period
|
Rate of premature discontinuation of study interventions due to safety-related reasons.
Unit: %.
|
During each APRV experimental intervention period
|
|
Inspired oxygen fraction (FiO₂)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Set inspired oxygen fraction, obtained directly from ventilator readings, recorded at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial pH
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial blood pH measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial partial pressure of oxygen (PaO₂)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial partial pressure of oxygen measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial partial pressure of carbon dioxide (PaCO₂)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial partial pressure of carbon dioxide measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial oxygen saturation (SaO₂)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial oxygen saturation measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: %.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Bicarbonate (HCO₃-)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Serum bicarbonate (HCO₃-) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Base excess (BE)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Base excess (BE) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Arterial lactate (Lac)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Arterial lactate (Lac) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmol/L.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
PaO₂/FiO₂ ratio
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
PaO₂/FiO₂ ratio calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Alveolar-arterial oxygen difference (A-aDO₂)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Alveolar-arterial oxygen difference calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization).
Unit: mmHg.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Correlation analysis among multiple respiratory-hemodynamic-diaphragm parameters
Prazo: Corresponding study time points
|
Explore the correlations among EIT parameters, respiratory mechanics, blood gas analysis, hemodynamics and diaphragm function across three study conditions.
|
Corresponding study time points
|
|
Ventilatory ratio (VR)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Ventilatory ratio (VR), a calculated index reflecting pulmonary dead-space and lung injury severity, is computed from minute ventilation and arterial CO₂ values assessed at baseline and under three APRV experimental conditions.
Unit: unitless.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Expired tidal volume (VTe)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Expired tidal volume assessed at baseline and under three APRV experimental conditions.
Unit: mL.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Total respiratory rate
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Total respiratory rate assessed at baseline and under three APRV experimental conditions.
Unit: breaths/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Total minute ventilation
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Total minute ventilation assessed at baseline and under three APRV experimental conditions.
Unit: L/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
|
Spontaneous minute ventilation
Prazo: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Spontaneous component of minute ventilation assessed under two APRV experimental conditions only when spontaneous breathing was present, derived directly from ventilator readings.
Unit: L/min.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Proportion of spontaneous minute ventilation
Prazo: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
Proportion of spontaneous minute ventilation relative to total minute ventilation, calculated under two APRV experimental conditions only when spontaneous breathing was present.
Unit: %.
|
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
|
|
Mechanical power (MP)
Prazo: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Mechanical power of ventilation as an indicator of ventilator-induced lung injury (VILI) risk, obtained directly from ventilator readings at baseline and under three APRV experimental conditions.
Unit: J/min.
|
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: xiaojing zou, MD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- PROTO-APRV-2026-01
- MR-42-26-065895 (Outro identificador: National Medical Research Registration and Filing Information System of China)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .